Today's 'Technical 420" Article Isodiol: Positioned for Huge Growth After Closing a Major Acquisition
Isodiol International (ISOL.CN) (ISOLF) is one of the Canadian cannabis companies capitalizing on the recent uptick in M&A transactions and we are favorable on the moves the Global Bioactive CBD innovator has made.
Last week, Isodiol announced a significant milestone and completed the acquisition of Biosynthesis Pharma Group (BSPG) and commenced construction on a state-of-the-art processing facility in China for the extraction of cannabinoids and terpenes from organic hemp. In 2017, Isodiol entered a agreement to acquire BSPG, which produces cannabinoids through proprietary extraction methodologies that are used in pharmaceutical applications.
This acquisition is massive and will allow Isodiol to produce significantly more product. On a daily basis, the new facility can process more than 15 metric tons of hemp biomass for the extraction of cannabinoids and terpenes for use in medical, nutraceutical, food, and cosmetic industries. Isodiol believes that this will facility has the highest capacity for processing CBD in the world and expects the facility to be completed by the first quarter of 2019.
Isodiol is focused on capitalizing on a global opportunity and we are bullish on the company’s leverage to several burgeoning markets. In 2018, Isodiol has been under considerable pressure and the shares have fallen approx. 30% during this time. We think this weakness is overdone and see considerable upside to current levels. Isodiol has been nothing short of an execution story and this is a stock that investors need to watch.